The Association of Visceral Adiposity Index With Progression of Chronic Kidney Disease
1 other identifier
observational
129
1 country
1
Brief Summary
The visceral adiposity index (VAI) has been developed, an indicator for the metabolic function of VAT. Previous studies have confirmed the association between the VAI and CKD prevalence. In this study, we attempted to investigate the association between estimated glomerular filtration rate (eGFR) decline and visceral adiposity.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Dec 2017
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 12, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 30, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2019
CompletedFirst Submitted
Initial submission to the registry
October 12, 2020
CompletedFirst Posted
Study publicly available on registry
October 19, 2020
CompletedOctober 19, 2020
October 1, 2020
12 months
October 12, 2020
October 12, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
progression of chronic kidney disease
increase in eGFR of chronic kidney disease patients in one year
one year
Interventions
estimated glomerular filtration rate
Eligibility Criteria
Chronic kidney disease patients who were followed up in the Nephrology Department of the Usak University Research and Training Hospital for at least 1 year between December 2017 and November 2018.
You may qualify if:
- patients with stage 2-5 CKD
- aged 18 and 80 years
- were not on dialysis
- patients were followed up in the Nephrology Department of the Usak University Research and Training Hospital for at least 1 year between December 2017 and November 2018.
You may not qualify if:
- missing data, patients older than 80 years, patients taking cholesterol and lipid lowering drugs and/or steroids.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Uşak Universitylead
Study Sites (1)
Usak University
Uşak, Select One, 64200, Turkey (Türkiye)
Related Publications (2)
Kramer H, Luke A, Bidani A, Cao G, Cooper R, McGee D. Obesity and prevalent and incident CKD: the Hypertension Detection and Follow-Up Program. Am J Kidney Dis. 2005 Oct;46(4):587-94. doi: 10.1053/j.ajkd.2005.06.007.
PMID: 16183412BACKGROUNDAmato MC, Giordano C. Visceral adiposity index: an indicator of adipose tissue dysfunction. Int J Endocrinol. 2014;2014:730827. doi: 10.1155/2014/730827. Epub 2014 Apr 14.
PMID: 24829577BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Zelal Adibelli
Uşak University
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- CROSS SECTIONAL
- Target Duration
- 1 Year
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Prof. Zelal Adibelli
Study Record Dates
First Submitted
October 12, 2020
First Posted
October 19, 2020
Study Start
December 12, 2017
Primary Completion
November 30, 2018
Study Completion
June 30, 2019
Last Updated
October 19, 2020
Record last verified: 2020-10